<DOC>
	<DOCNO>NCT00004842</DOCNO>
	<brief_summary>OBJECTIVES : I. Assess safety effectiveness budesonide patient primary sclerosing cholangitis primary biliary cirrhosis experience suboptimal response ursodeoxycholic acid . II . Estimate efficacy therapy patient group mean evaluate feasibility long-term randomized trial .</brief_summary>
	<brief_title>Pilot Study Budesonide Patients With Primary Sclerosing Cholangitis</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Patients receive budesonide mouth 3 time daily minimum 6 month . If liver biochemistry become normal , dosage reduce daily . Treatment discontinue 1 year .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Cholangitis</mesh_term>
	<mesh_term>Cholangitis , Sclerosing</mesh_term>
	<mesh_term>Liver Cirrhosis , Biliary</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Pathologically confirm primary sclerosing cholangitis ( PSC ) meeting follow criterion : Chronic cholestatic disease least 6 month Liver biopsy within past 6 month compatible diagnosis PSC Intra and/or extrahepatic biliary duct obstruction , beading , narrow OR Pathologically confirm primary biliary cirrhosis ( PBC ) experience suboptimal response ursodeoxycholic acid meeting follow criterion : Chronic cholestatic liver disease least 6 month Positive antimitochondrial antibody No biliary obstruction ultrasound , CT , cholangiography Prior liver biopsy compatible diagnosis PBC Received ursodeoxycholic acid least 6 month Prior/Concurrent Therapy Biologic therapy : At least 3 month since prior Dpenicillamine No plan transplantation least 1 year Chemotherapy : At least 3 month ( 6 month PBC ) since prior cyclosporin , colchicine , azathioprine , methotrexate At least 6 month since prior chlorambucil ( PBC ) Endocrine therapy : At least 3 month ( 6 month PBC ) since prior corticosteroid Surgery : No prior intraductal stone operation biliary tree except cholecystectomy ( PSC ) Other : At least 3 month since prior pentoxifylline , ursodeoxycholic acid , nicotine ( PSC ) At least 6 month since prior chenodeoxycholic acid ( PBC ) Patient Characteristics Life expectancy : At least 3 year Hematopoietic : Not specify Hepatic : Alkaline phosphatase least 2 time upper limit normal No chronic hepatitis B infection No hepatitis C infection No autoimmune hepatitis Bilirubin great 4 mg/dL ( PBC ) Cardiovascular : No severe cardiopulmonary disease Other : No concurrent advance malignancy At least 3 month since prior inflammatory bowel disease require specific treatment except maintenance therapy ( PSC ) No anticipate need transplantation within 1 year Not pregnant No liver disease etiology : Chronic alcoholic liver disease Hemochromatosis Wilson 's disease Congenital biliary disease Cholangiocarcinoma No recurrent ascend cholangitis require hospitalization 2 time per year ( PSC ) At least 1 year since prior active peptic ulcer No recurrent variceal bleed No spontaneous encephalopathy No diureticresistant ascites</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 1998</verification_date>
	<keyword>cirrhosis</keyword>
	<keyword>gastrointestinal disorder</keyword>
	<keyword>primary biliary cirrhosis</keyword>
	<keyword>primary sclerosing cholangitis</keyword>
	<keyword>rare disease</keyword>
</DOC>